Copyright © 1996, 1997, 2001 by Galen Daryl Knight
and VitaleTherapeutics, Inc.
Specific Targeting, Even of Immune Tumors
Further analysis of results reported in Cancer
Research indicate that vitaletheine modulators and related compounds
may be unique in their ability to use the immune system to selectively
treat cancers of the immune system. NS-1 myeloma is a non-secreting plasmacytoma
of the B-cell lineage, i.e., a cancerous antibody-producing immune tumor
which does not release its antibodies into the medium. Treatments with
the vitaletheine modulator were stopped on day 47 (almost 7 weeks) and
protracted survival after this time indicates either a cure for the disease
in all of the juvenile mice treated with 100 pg/kg, or at least a continuing
immune surveillance to eliminate any recurring tumor. Thus, this approach
is sufficiently specific to stop the cancer cells without harming rapidly
growing normal (or healthy) cells. This capacity should be particularly
useful in the treatment of young children with cancer, i.e., effective
treatment without causing the complications of retarded growth and development
associated with other chemo- and radio-therapies.
GO TO: